Protalix BioTherapeutics, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
Protalix BioTherapeutics, Inc. (PLX) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $895.00 thousand for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-07.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2013-11-07
- Protalix BioTherapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2013-09-30 was $250.00K.
- Protalix BioTherapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2013-06-30 was $298.00K.
- Protalix BioTherapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2013-03-31 was $347.00K, a 168.99% increase year-over-year.
- Protalix BioTherapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2012-03-31 was $129.00K.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2013-09-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $548.00K derived: sum of 2 quarters · filed 2013-11-07 | $895.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $298.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $645.00K 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $347.00K 10-Q · filed 2013-05-09 | ||
| 2012-09-30 | $4.22M 10-Q · filed 2013-11-07 | ||
| 2012-03-31 | $129.00K 10-Q · filed 2013-05-09 | ||
| 2011-09-30 | $730.00K 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |